Related Experiment Videos

Triptolide suppresses proinflammatory cytokine-induced matrix metalloproteinase and aggrecanase-1 gene expression in

Abdelhamid Liacini1, Judith Sylvester, Muhammad Zafarullah

  • 1Department of Medicine, University of Montreal and CHUM Research Center, Notre-Dame Hospital, Montreal, Que., Canada H2L 4M1.

Biochemical and Biophysical Research Communications
|January 5, 2005
PubMed

Insights

A purified derivative of Tripterygium wilfordii Hook F (TWHF), PG490 (triptolide), effectively inhibited cartilage-degrading enzymes in arthritis models. This suggests PG490

Area of Science:

  • Biochemistry
  • Pharmacology
  • Rheumatology

Background:

  • Rheumatoid arthritis and osteoarthritis (OA) involve cartilage degeneration driven by proinflammatory cytokines.
  • Matrix metalloproteinases (MMPs) and aggrecanases (ADAMTS) are key enzymes responsible for this breakdown.
  • The therapeutic potential of Tripterygium wilfordii Hook F (TWHF) and its derivatives for arthritis remains largely unexplored.

Purpose of the Study:

  • To investigate the effects of PG490 (triptolide), a purified TWHF derivative, on the expression of cartilage-degrading proteases.
  • To elucidate the anti-arthritic mechanisms of PG490 concerning cartilage protection.

Main Methods:

  • PG490's impact on cytokine-stimulated MMP-3, MMP-13, and ADAMTS4 gene expression was assessed.
  • Experiments were conducted using primary human OA chondrocytes, bovine chondrocytes, SW1353 cells, and human synovial fibroblasts.
  • The efficacy of triptolide was further evaluated in human and bovine cartilage explants.

Main Results:

  • PG490 significantly inhibited the gene expression of MMP-3 and MMP-13 induced by cytokines in various cell types.
  • Triptolide demonstrated effectiveness at low concentrations, blocking IL-1-induced MMP-13 in cartilage explants.
  • Both TWHF extract and PG490 suppressed IL-1, IL-17, and TNF-alpha-induced ADAMTS-4 expression in bovine chondrocytes.

Conclusions:

  • PG490 exhibits potent inhibition of major cartilage-degrading enzymes, MMPs and ADAMTS4.
  • The findings suggest PG490 can protect cartilage from protease-driven breakdown.
  • PG490's immunosuppressive, anti-inflammatory, and cartilage-protective properties indicate its potential as a novel therapeutic agent for arthritis.

Related Concept Videos

Role of Matrix Metalloproteases in Degradation of ECM01:23

Role of Matrix Metalloproteases in Degradation of ECM

Matrix metalloproteases (MMPs) are enzymes involved in the hydrolysis of proteins and glycoproteins of the extracellular matrix. MMPs are essential for the migration and proliferation of cells through the dense matrix network, throughout embryonic development, and throughout morphogenesis. The first MMP activity discovered was a collagenase in a tadpole's tail undergoing metamorphosis. The active collagen deposition and modifications lead to the morphogenesis of tadpoles into the adult body.
A...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...